MARKET

BVAXF

BVAXF

Biovaxys Technol
OTCMQB
0.036
-0.003
-6.49%
Closed 15:50 03/21 EDT
OPEN
0.036
PREV CLOSE
0.039
HIGH
0.036
LOW
0.036
VOLUME
8
TURNOVER
0
52 WEEK HIGH
0.065
52 WEEK LOW
0.030
MARKET CAP
10.49M
P/E (TTM)
-1.6822
1D
5D
1M
3M
1Y
5Y
1D
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Barchart · 4d ago
Weekly Report: what happened at BVAXF last week (0310-0314)?
Weekly Report · 5d ago
Weekly Report: what happened at BVAXF last week (0303-0307)?
Weekly Report · 03/10 11:40
BioVaxys Technology Corp. Receives Management Cease Trade Order Amid Filing Delays
TipRanks · 03/04 00:09
BIOVAXYS TECHNOLOGY CORP. GRANTED MANAGEMENT CEASE TRADE ORDER
Reuters · 03/03 23:23
Weekly Report: what happened at BVAXF last week (0224-0228)?
Weekly Report · 03/03 11:39
Weekly Report: what happened at BVAXF last week (0217-0221)?
Weekly Report · 02/24 11:39
BIOVAXYS ANNOUNCES DEBT SETTLEMENT AGREEMENT, EXTENSION OF PRIVATE PLACEMENT CLOSING DATE AND CLOSING OF THE FOURTH AND FINAL TRANCHE OF PRIVATE PLACEMENT
Reuters · 02/20 20:03
More
About BVAXF
BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

Webull offers Biovaxys Technology Corp stock information, including OTCMQB: BVAXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVAXF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BVAXF stock methods without spending real money on the virtual paper trading platform.